Latest chronic kidney disease and diabetes guidance published

By Editor
10th October 2022
Chronic Kidney Disease, Research

Two top healthcare organisations have released new consensus on the management of chronic kidney disease and diabetes. 

The American Diabetes Association® (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) have published new recommendations on how to improve clinical outcomes of people with diabetes and chronic kidney disease (CKD).

The report covers a range of different topics, including glycemia monitoring, lifestyle therapies, treatment goals, pharmacologic management and CKD screening and diagnosis.

In addition, the new consensus also includes specific guidance on the use of renin-angiotensin system inhibitors, metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist.

The updated guideline was reviewed and developed by a joint group of ADA and KDIGO representatives.

To read the consensus update, click here.

Comments (0)